Targeted drug tested for Tough-to-Treat stomach tumors
NCT ID NCT06087263
Summary
This study is testing whether the drug regorafenib can help control rare, hard-to-treat types of gastrointestinal stromal tumors (GIST) that have specific genetic mutations. It is for adults whose cancer has continued to grow despite standard first-line treatment. The main goal is to see if the drug can slow or stop tumor growth in these specific patient groups.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.